Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:advances |
Advancements in biotechnology technology
|
| gptkbp:awards |
Industry awards for innovation
|
| gptkbp:biotech_sector |
Active in the biotech sector
|
| gptkbp:business_model |
Innovative business model
|
| gptkbp:ceo |
gptkb:Ali_Tehrani
|
| gptkbp:clinical_trial |
Ongoing clinical trials
Published clinical data Various phases of clinical trials |
| gptkbp:collaboration |
Academic institutions
|
| gptkbp:collaborations |
Collaborative research projects
|
| gptkbp:community_engagement |
Active in local communities
|
| gptkbp:community_support |
Support for local communities
|
| gptkbp:conference |
Participates in industry conferences
|
| gptkbp:employees |
Over 200
|
| gptkbp:financial_performance |
Strong financial performance
|
| gptkbp:financial_reports |
Quarterly financial reports
|
| gptkbp:focus |
Autoimmune diseases
Cancer therapeutics Patient-centric approach |
| gptkbp:founded |
gptkb:2003
|
| gptkbp:founder |
gptkb:Ali_Tehrani
|
| gptkbp:funding |
Secured research funding
|
| gptkbp:future_plans |
Plans for future growth
|
| gptkbp:global_presence |
Global presence in biotechnology
|
| gptkbp:head_of_state |
Active in business development
|
| gptkbp:headcount |
Growing workforce
|
| gptkbp:headquarters |
gptkb:Vancouver,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zymeworks Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:innovation |
Focus on innovative solutions
|
| gptkbp:instruction_set |
Diverse pipeline of drug candidates
|
| gptkbp:invention |
Multiple patents in biotechnology
|
| gptkbp:investment |
Various venture capital firms
Dedicated investor relations team Investing in research and development |
| gptkbp:leadership |
Experienced management team
|
| gptkbp:location |
gptkb:Canada
gptkb:United_States |
| gptkbp:market_cap |
Market capitalization in billions
|
| gptkbp:marketing_strategy |
Aggressive market strategy
|
| gptkbp:mission |
To improve patient outcomes
|
| gptkbp:network |
Strong networking in biotech community
|
| gptkbp:partnership |
Various pharmaceutical companies
|
| gptkbp:partnerships |
Exploring partnership opportunities
Strategic partnerships with biotech firms |
| gptkbp:products |
Zymeworks' therapeutic proteins
|
| gptkbp:publications |
Numerous scientific publications
|
| gptkbp:regulatory_compliance |
Seeking regulatory approvals for drugs
|
| gptkbp:research_and_development |
Innovative drug candidates
|
| gptkbp:research_areas |
Multiple therapeutic areas
|
| gptkbp:research_focus |
gptkb:Oncology
Immunology |
| gptkbp:revenue |
Reported revenue in millions
|
| gptkbp:services |
Drug development
|
| gptkbp:social_responsibility |
Commitment to corporate social responsibility
|
| gptkbp:stock_symbol |
ZYME
|
| gptkbp:strategic_goals |
Achieving strategic goals in drug development
|
| gptkbp:subsidiary |
gptkb:Zymeworks_US,_Inc.
|
| gptkbp:sustainability |
Commitment to sustainable practices
|
| gptkbp:technology |
Protein engineering technology
|
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:training |
Focus on employee training
|
| gptkbp:treatment |
Improving clinical outcomes
|
| gptkbp:trends |
Monitoring market trends
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vision |
Transforming the treatment of diseases
|
| gptkbp:website |
www.zymeworks.com
|
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Ariad_Pharmaceuticals gptkb:Zymeworks'_Zymeworks_2.0_platform |
| gptkbp:bfsLayer |
5
|